MedPath

Boehringer Ingelheim USA Corporation

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website
Clinical Trials
Related News

Assessment of the Effect of BI 201335 on the QT Interval in Healthy Female and Male Subjects

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: BI 201335 low dose
Drug: BI 201335 placebo
Drug: BI 201335 high dose
First Posted Date
2014-07-08
Last Posted Date
2014-07-18
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
56
Registration Number
NCT02182310

Investigation of the Potential Pharmacokinetic Interaction Between Nevirapine, Abacavir and Amprenavir in HIV-1 Infected Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Naive Adults

Phase 1
Terminated
Conditions
HIV Infections
Interventions
First Posted Date
2014-07-08
Last Posted Date
2014-07-14
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
8
Registration Number
NCT02182765

Efficacy and Tolerability of Metamizol in Patients With Episodic Moderate Headache

Phase 3
Completed
Conditions
Migraine Disorders
Interventions
Drug: Acetylsalicylic acid (ASA)
First Posted Date
2014-07-08
Last Posted Date
2014-07-08
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
417
Registration Number
NCT02183220

Bioavailability of Warfarin After Coadministration With Multiple Doses of BI 1356 Compared to the Bioavailability of Warfarin Alone in Healthy Male Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2014-07-08
Last Posted Date
2014-07-08
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
18
Registration Number
NCT02183389

Dose Proportionality of Different Dose Strengths of Linagliptin Tablets After Oral Administration to Healthy Male and Female Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Linagliptin, high dose
Drug: Linagliptin, low dose
Drug: Linagliptin, medium dose
First Posted Date
2014-07-08
Last Posted Date
2014-07-08
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
12
Registration Number
NCT02183480

Telmisartan Compared to Losartan + Hydrochlorothiazide in Patients With Mild-to-moderate Essential Hypertension

Phase 3
Completed
Conditions
Hypertension
Interventions
Drug: Placebo
First Posted Date
2014-07-08
Last Posted Date
2014-07-08
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
715
Registration Number
NCT02183701

Pharmacokinetics and Pharmacodynamics of BI 1356 in Subjects With Different Degrees of Liver Impairment as Compared to Healthy Subjects

Phase 1
Completed
Conditions
Hepatic Insufficiency
Interventions
First Posted Date
2014-07-08
Last Posted Date
2014-07-08
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
33
Registration Number
NCT02183376

A Study to Access the Efficacy and Safety of Meloxicam in Patients With Osteoarthritis of the Knee

Phase 4
Completed
Conditions
Osteoarthritis
Interventions
First Posted Date
2014-07-08
Last Posted Date
2014-07-08
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
30
Registration Number
NCT02183116

Tolerability and Potential ECG Effects After a Single Oral Dose of Pentoxyverine Citrate in Healthy Male and Female Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Placebo
First Posted Date
2014-07-08
Last Posted Date
2014-07-08
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
18
Registration Number
NCT02183649

A Confirmation Study of Combivent HFA Inhalation Aerosol in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Phase 2
Completed
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Drug: Placebo Combivent HFA
Drug: Placebo Combivent (CFC)
First Posted Date
2014-07-08
Last Posted Date
2018-08-31
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
66
Registration Number
NCT02182674
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy